# Lantheus Medical Imaging clinical trials: 30 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials with Lantheus Medical Imaging as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Lantheus Medical Imaging: 30 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/lantheus-medical-imaging

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 21, 2026 | NCT07831824 | Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW \[Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic... | Lantheus Medical Imaging | Phase 2/3 | Recruiting | Prostate Cancer | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831824) |
| January 22, 2026 | NCT07357519 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | Lantheus Medical Imaging | Phase 1/2 | Recruiting | Relapsed / Refractory Osteosarcoma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07357519) |
| July 25, 2025 | NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC | Lantheus Medical Imaging | Phase 2/3 | Withdrawn | Clear Cell Renal Cell Carcinoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07084909) |
| March 7, 2024 | NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Lantheus Medical Imaging | Phase 1/2 | Recruiting | Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06298916) |
| October 10, 2023 | NCT06074510 | PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer | Lantheus Medical Imaging | Phase 4 | Completed | Prostate Cancer | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06074510) |
| September 13, 2023 | NCT06033001 | Expanded Access Treatment with \[Lu-177\]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic... | Lantheus Medical Imaging | Not applicable | Temporarily not available | Castration-Resistant Prostatic Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06033001) |
| February 3, 2023 | NCT05712473 | An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer | Lantheus Medical Imaging | Observational | Active not recruiting | Prostate Cancer | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05712473) |
| October 25, 2018 | NCT03719612 | DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Lantheus Medical Imaging | Phase 3 | Completed | Cardiac Disease | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03719612) |
| June 27, 2018 | NCT03571672 | DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Lantheus Medical Imaging | Phase 3 | Completed | Cardiac Disease | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03571672) |
| September 10, 2012 | NCT01681524 | Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI | Lantheus Medical Imaging | Phase 3 | Withdrawn | Coronary Artery Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01681524) |
| May 4, 2011 | NCT01347710 | A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. | Lantheus Medical Imaging | Phase 3 | Completed | Coronary Artery Disease | 795 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01347710) |
| February 18, 2011 | NCT01299649 | Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY® | Lantheus Medical Imaging | Observational | Completed | Cardiovascular Disease | 4,300,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01299649) |
| June 2, 2010 | NCT01135316 | Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR | Lantheus Medical Imaging | Observational | Completed | Nephrogenic Systemic Fibrosis | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01135316) |
| March 11, 2010 | NCT01085175 | Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing | Lantheus Medical Imaging | Phase 2 | Withdrawn | Heart Failure | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01085175) |
| March 11, 2010 | NCT01085162 | A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD) | Lantheus Medical Imaging | Observational | Withdrawn | Coronary Artery Disease (CAD) | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01085162) |
| June 30, 2009 | NCT00930631 | Study of \[3H\] BMS747158 in Healthy Male Subjects | Lantheus Medical Imaging | Phase 1 | Completed | Coronary Artery Disease | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00930631) |
| June 11, 2009 | NCT00918866 | A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure | Lantheus Medical Imaging | Phase 4 | Completed | Pulmonary Heart Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00918866) |
| May 1, 2009 | NCT00891241 | A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure | Lantheus Medical Imaging | Phase 1 | Completed | Heart Failure | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00891241) |
| February 23, 2009 | NCT00849108 | Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158 | Lantheus Medical Imaging | Phase 2 | Completed | Ischemia | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00849108) |
| July 1, 2008 | NCT00707538 | A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress | Lantheus Medical Imaging | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00707538) |
| July 1, 2008 | NCT00707499 | A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158 | Lantheus Medical Imaging | Phase 1 | Completed | Healthy | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00707499) |
| February 28, 2008 | NCT00625365 | A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice | Lantheus Medical Imaging | Phase 4 | Completed | Cardiovascular Disease | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00625365) |
| November 20, 2006 | NCT00401687 | DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function | Lantheus Medical Imaging | Phase 4 | Completed | Ventricular Ejection Fraction | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00401687) |
| September 13, 2005 | NCT00162370 | A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease | Lantheus Medical Imaging | Phase 4 | Completed | Coronary Artery Disease, Heart Disease | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00162370) |
| September 13, 2005 | NCT00162357 | Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty | Lantheus Medical Imaging | Phase 4 | Completed | Diabetes Mellitus, Type 2, Coronary Restenosis | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00162357) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 3 |
| Phase 2 | 3 |
| Phase 2/3 | 2 |
| Phase 3 | 5 |
| Phase 4 | 8 |
| Not applicable | 1 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Withdrawn | 4 |
| Recruiting | 3 |
| Active not recruiting | 1 |
| Temporarily not available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Coronary Artery Disease | 6 |
| Heart Diseases | 4 |
| Prostatic Neoplasms | 3 |
| Cardiovascular Diseases | 3 |
| Heart Failure | 2 |
| Mucocutaneous Lymph Node Syndrome | 2 |
| Liver Diseases | 1 |
| Carcinoma, Renal Cell | 1 |
| Kidney Neoplasms | 1 |
| Ischemia | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Coronary Restenosis | 1 |
| Nephrogenic Fibrosing Dermopathy | 1 |
| Kidney Diseases | 1 |
| Pulmonary Heart Disease | 1 |
| Sarcoma | 1 |
| Esophageal Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Death, Sudden, Cardiac | 1 |
| Osteosarcoma | 1 |
| Coronary Disease | 1 |
| Arteriosclerosis | 1 |
| Arterial Occlusive Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Shoe factory manufacturers in the United States](https://specstream.ai/data/businesses/shoe-factory-manufacturers/united-states)
- [Polynesian restaurants in the United States](https://specstream.ai/data/businesses/polynesian-restaurants/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
- [Geriatric medicine practices in the United States](https://specstream.ai/data/businesses/geriatric-medicine-practices/united-states)
- [Electronic parts suppliers in the United States](https://specstream.ai/data/businesses/electronic-parts-suppliers/united-states)
